{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:19:05Z","timestamp":1788952745291,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370263"],"award-info":[{"award-number":["82370263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82530014"],"award-info":[{"award-number":["82530014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L256012"],"award-info":[{"award-number":["L256012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0531200"],"award-info":[{"award-number":["2024ZD0531200"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2021YFA0805100"],"award-info":[{"award-number":["2021YFA0805100"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.yjmcc.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:43:40Z","timestamp":1787388220000},"page":"69-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Icosapent ethyl activates GPR120 to improve post-myocardial infarction cardiac remodeling by suppressing CXCR3+ inflammatory cells"],"prefix":"10.1016","volume":"219","author":[{"given":"Lu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.yjmcc.2026.08.010_bb0005","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2019.03.531","article-title":"From early pharmacology to recent pharmacology interventions in acute coronary syndromes: JACC state-of-the-art review","volume":"74","author":"Szummer","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.yjmcc.2026.08.010_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028932","article-title":"Temporal trends in infarct severity outcomes in ST-segment-elevation myocardial infarction: a cardiac magnetic resonance imaging study","volume":"12","author":"Lechner","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"19","key":"10.1016\/j.yjmcc.2026.08.010_bb0015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur. Heart J."},{"issue":"9966","key":"10.1016\/j.yjmcc.2026.08.010_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(14)60921-1","article-title":"ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-retrospective acute myocardial infarction study): a retrospective analysis of hospital data","volume":"385","author":"Li","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0025","first-page":"40","article-title":"Five-year risk of heart failure and death following myocardial infarction with cardiogenic shock: a nationwide cohort study","volume":"10","author":"Lauridsen","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"15","key":"10.1016\/j.yjmcc.2026.08.010_bb0030","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association","volume":"135","author":"Siscovick","year":"2017","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.yjmcc.2026.08.010_bb0035","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.yjmcc.2026.08.010_bb0040","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jacc.2020.08.073","article-title":"Circulating Omega-3 fatty acids and incident adverse events in patients with acute myocardial infarction","volume":"76","author":"L\u00e1zaro","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0045","article-title":"Decreased circulating omega-3 fatty acids increase the risk of myocardial infarction: a two-sample Mendelian randomization study","volume":"11","author":"Wang","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.plipres.2016.05.001","article-title":"Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults","volume":"63","author":"Stark","year":"2016","journal-title":"Prog. Lipid Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.yjmcc.2026.08.010_bb0060","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.yjmcc.2026.08.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine Omega-3 supplementation and cardiovascular disease: an updated Meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"10","key":"10.1016\/j.yjmcc.2026.08.010_bb0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11886-020-01356-4","article-title":"Icosapent ethyl: niche drug or for the masses?","volume":"22","author":"Bazarbashi","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024999","article-title":"Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"17","key":"10.1016\/j.yjmcc.2026.08.010_bb0080","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/ehjci\/jead063","article-title":"Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT","volume":"24","author":"Rabbat","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.yjmcc.2026.08.010_bb0095","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcad.2021.08.003","article-title":"The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization","volume":"69","author":"Bhatt","year":"2021","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"23","key":"10.1016\/j.yjmcc.2026.08.010_bb0105","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133684","article-title":"Eligibility for icosapent ethyl 1-3 months after acute coronary syndrome and the risk for myocardial re-infarction: data from the CALLINICUS-Hellas registry","volume":"440","author":"Rallidis","year":"2025","journal-title":"Int. J. Cardiol."},{"issue":"22","key":"10.1016\/j.yjmcc.2026.08.010_bb0115","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.yjmcc.2026.08.010_bb0120","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2024.02.016","article-title":"Lipoprotein(a) blood levels and cardiovascular risk reduction with Icosapent ethyl","volume":"83","author":"Szarek","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.yjmcc.2026.08.010_bb0125","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108172","article-title":"Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl\/eicosapentaenoic acid","volume":"237","author":"Chapman","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf602","article-title":"Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT","author":"Gurevitz","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.08.010_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ehjcvp\/pvac045","article-title":"Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking","volume":"9","author":"Miller","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.026756","article-title":"Cardiovascular benefits of Icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT","volume":"12","author":"Olshansky","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038656","article-title":"Cardiovascular outcomes with icosapent ethyl by baseline low-density lipoprotein cholesterol: a secondary analysis of the REDUCE-IT randomized trial","volume":"14","author":"Aggarwal","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.08.010_bb0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and Eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12944-023-01838-8","article-title":"Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China","volume":"22","author":"Wang","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.08.010_bb0165","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.08.010_bb0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14779072.2020.1749596","article-title":"Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol","volume":"18","author":"Bazarbashi","year":"2020","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-025-03033-8","article-title":"Cardioprotective mechanism of omega-3 fatty acid icosapent ethyl (IPE) in cardiomyocytes: role in high glucose and shear stress-induced mechano-transduction dysregulation","volume":"25","author":"Pesapane","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.08.010_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004560","article-title":"Long-term administration of eicosapentaenoic acid improves post-myocardial infarction cardiac remodeling in mice by regulating macrophage polarization","volume":"6","author":"Takamura","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"40","key":"10.1016\/j.yjmcc.2026.08.010_bb0185","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.yjmcc.2026.08.010_bb0190","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1111\/jcmm.15575","article-title":"Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: role of GPR120-mediated connexin43 phosphorylation","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0195","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: from molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem. Soc. Trans."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.08.010_bb0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance","volume":"1851","author":"Calder","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0205","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/jn\/135.7.1745","article-title":"Dietary (n-3) polyunsaturated fatty acids modulate murine Th1\/Th2 balance toward the Th2 pole by suppression of Th1 development","volume":"135","author":"Zhang","year":"2005","journal-title":"J. Nutr."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.08.010_bb0210","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s42255-024-01070-3","article-title":"The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid","volume":"6","author":"Zhou","year":"2024","journal-title":"Nat. Metab."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0215","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh","year":"2010","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.08.010_bb0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm.3614","article-title":"A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice","volume":"20","author":"Oh","year":"2014","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2021.09.018","article-title":"GPR120 inhibits colitis through regulation of CD4(+) T cell interleukin 10 production","volume":"162","author":"Yang","year":"2022","journal-title":"Gastroenterology"},{"issue":"25","key":"10.1016\/j.yjmcc.2026.08.010_bb0230","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMra1008153","article-title":"N-3 fatty acids in cardiovascular disease","volume":"364","author":"De Caterina","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.yjmcc.2026.08.010_bb0235","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0240","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain \u03c9-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041046","article-title":"Serum long-chain n-3 polyunsaturated fatty acids, mercury, and risk of sudden cardiac death in men: a prospective population-based study","volume":"7","author":"Virtanen","year":"2012","journal-title":"PLoS One"},{"issue":"9567","key":"10.1016\/j.yjmcc.2026.08.010_bb0250","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.yjmcc.2026.08.010_bb0255","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M062034","article-title":"EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4","volume":"56","author":"Eclov","year":"2015","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.08.010_bb0260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jchf.2019.03.008","article-title":"Predicting risk for incident heart failure with Omega-3 fatty acids: from MESA","volume":"7","author":"Block","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0265","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5551\/jat.21022","article-title":"Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia","volume":"21","author":"Kohashi","year":"2014","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1229130","article-title":"Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events","volume":"10","author":"Le","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.08.010_bb0275","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/CIRCULATIONAHA.123.065530","article-title":"Role of polyunsaturated fat in modifying cardiovascular risk associated with family history of cardiovascular disease: pooled De novo results from 15 observational studies","volume":"149","author":"Laguzzi","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.yjmcc.2026.08.010_bb0280","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","article-title":"Effect of Omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial","volume":"134","author":"Heydari","year":"2016","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.yjmcc.2026.08.010_bb0285","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.yjmcc.2026.08.010_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9111224","article-title":"The involvement of CXC motif chemokine ligand 10 (CXCL10) and its related chemokines in the pathogenesis of coronary artery disease and in the COVID-19 vaccination: a narrative review","volume":"9","author":"Karimabad","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cpdd.1130","article-title":"Pharmacokinetics of icosapent ethyl: an open-label, multiple oral dose, parallel design study in healthy Chinese subjects","volume":"12","author":"Yuan","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bcp.2016.03.017","article-title":"Metabolism meets immunity: the role of free fatty acid receptors in the immune system","volume":"114","author":"Alvarez-Curto","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fphar.2014.00236","article-title":"Free fatty acid receptors as therapeutic targets for the treatment of diabetes","volume":"5","author":"Ichimura","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0310","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4396368","article-title":"The CXCL10\/CXCR3 Axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart","volume":"2016","author":"Altara","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0315","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125527","article-title":"CXCR3 regulates CD4+ T cell cardiotropism in pressure overload-induced cardiac dysfunction","volume":"4","author":"Ngwenyama","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0320","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.08.010_bb0325","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12265-016-9703-3","article-title":"CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study","volume":"9","author":"Altara","year":"2016","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13010116","article-title":"New markers for cardiovascular disease in psoriatic patients: preliminary study on monocyte phenotype, ADAMTS7, and mTOR activity","volume":"13","author":"Loyola","year":"2023","journal-title":"Metabolites"},{"issue":"47","key":"10.1016\/j.yjmcc.2026.08.010_bb0335","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1093\/eurheartj\/ehad665","article-title":"Targeting anti-CXCR3 autoantibodies as potential cardioprotective therapy: promises and challenges","volume":"44","author":"Tang","year":"2023","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.yjmcc.2026.08.010_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/biom11091355","article-title":"TNF-\u03b1 increases IP-10 expression in MCF-7 breast Cancer cells via activation of the JNK\/c-Jun pathways","volume":"11","author":"Kochumon","year":"2021","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.yjmcc.2026.08.010_bb0345","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.lfs.2004.04.024","article-title":"Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice","volume":"75","author":"Cavasin","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.yjmcc.2026.08.010_bb0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijcard.2021.07.036","article-title":"Sex-related differences in ventricular remodeling after myocardial infarction","volume":"339","author":"Aimo","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.yjmcc.2026.08.010_bb0355","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1067\/S0894-7317(03)00648-5","article-title":"Influence of sex on ventricular remodeling after myocardial infarction in mice","volume":"16","author":"Wu","year":"2003","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.08.010_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015672","article-title":"Molecular and cellular differences in cardiac repair of male and female mice","volume":"9","author":"Pullen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.08.010_bb0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.08.010_bb0370","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.medj.2024.03.009","article-title":"Icosapent ethyl modulates circulating vascular regenerative cell content: the IPE-PREVENTION CardioLink-14 trial","volume":"5","author":"Bakbak","year":"2024","journal-title":"Med"}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:50:39Z","timestamp":1788951039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282826001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"alternative-id":["S0022282826001288"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.08.010","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Icosapent ethyl activates GPR120 to improve post-myocardial infarction cardiac remodeling by suppressing CXCR3+ inflammatory cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}